Regeneron Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

18.12.13	Regeneron: FDA Accepts SBLA For EYLEA - Quick Facts (RTTNews)
22.11.13	Regeneron Says EYLEA Got Approval In Japan - Quick Facts (RTTNews)
22.11.13	Sanofi, Regeneron Report Positive Data With Sarilumab In Phase 3 Arthritis Trial (RTTNews)
22.11.13	Sanofi, Regeneron Report Positive Results With Sarilumab In First Phase 3 Trial (RTTNews)
07.11.13	Bayer HealthCare Submits MAA In European Union For EYLEA Injection (RTTNews)
05.11.13	Regeneron Pharma Q3 GAAP Profit Drops - Quick Facts (RTTNews)
21.10.13	Critical Alerts For Cisco, Chipotle Mexican Grill, Regeneron, SolarCity, and ARM Holdings Released By InvestorsObserver (PR Newswire)
21.10.13	Regeneron Pharma Reports Positive Topline Results For EYLEA Injection (RTTNews)
21.10.13	Regeneron Reports Positive Phase 3 Data for EYLEA® (aflibercept) Injection in Macular Edema Following Branch Retinal Vein Occlusion (PR Newswire)
16.10.13	Dividend Announcements, Earnings Release Scheduled, and Data Presentations from Clinical Studies - Research Report on Questcor, Regeneron, NPS, Incyte, and Nektar (PR Newswire)
16.10.13	Sanofi macht bei Entwicklung von neuem Cholesterinsenker Fortschritte (dpa-afx)
16.10.13	Sanofi, Regeneron Say Alirocumab Significantly Reduces Bad Cholesterol (RTTNews)
23.09.13	Conference Calls, New Appointments, Upcoming Presentations, Prospectus Filings and Acquisition Deal Updates - Research Report on Johnson & Johnson, WellPoint, Regeneron, Onyx, and MannKind (PR Newswire)
19.09.13	Critical Alerts For Cisco Systems, Petroleo Brasileiro S.A., General Motors (GM), Regeneron Pharmaceuticals, and Total S.A. Released By InvestorsObserver (PR Newswire)
18.09.13	Pipeline Developments, Product Recalls, Clinical Trial Results, Recognitions, and New Appointments - Research Report on Johnson & Johnson, Amgen, Regeneron, UnitedHealth, and Bristol-Myers (PR Newswire)
17.09.13	Regeneron to Present Phase 3 Data for EYLEA® (aflibercept) Injection in Diabetic Macular Edema at Upcoming Retina Society Meeting (PR Newswire)
14.09.13	Sanofi Likely To Repurchase 9% Stake Of L'Oreal (RTTNews)
10.09.13	Regeneron Names Robert Landry SVP, Finance & CFO - Quick Facts (RTTNews)
03.09.13	Pharmaceuticals Report Revolutionary Findings, Approved Treatments, Investor Conferences - Research Report on Celgene, Amgen, Biogen Idec, Regeneron, and Questcor (PR Newswire)
29.08.13	Regeneron:EC Oks Eylea Injection To Treat Visual Impairment Due To Macular Edema (RTTNews)
27.08.13	Regeneron Announces Upcoming 2013 Investor Conference Presentations (PR Newswire)
21.08.13	Biotech Companies Announce Financial Results and Receive New Patents - Research Report on Regeneron, Medivation, Incyte, Santarus, and ACADIA (PR Newswire)
19.08.13	Critical Alerts For Microsoft, Amarin, Regeneron Pharmaceuticals, Best Buy, and Harley Davidson Released By InvestorsObserver (PR Newswire)
09.08.13	Quarterly Financial Results and Development Program Updates - Research Report on Regeneron, DaVita, Celldex, Isis, and VIVUS (PR Newswire)
07.08.13	Regeneron Granted Fundamental Patents Covering Mouse Antibody Technology Used in VelocImmune® Mice (PR Newswire)
06.08.13	Regeneron : Eye Drug Meets Primary Endpoint In Diabetic Macular Edema Trials (RTTNews)
06.08.13	Regeneron Reports Second Quarter 2013 Financial and Operating Results (PR Newswire)
26.07.13	Regeneron Says CHMP Recommends For Approval Of Eylea Injection - Quick Facts (RTTNews)
24.09.12	MÄRKTE EUROPA/Schwache Konjunktursignale belasten (Dow Jones)
24.09.12	Bayer: Aflibercept für EU zur Zulassung bei feuchter altersbedingter Makula-Degeneration empfohlen (Aktiencheck)
08.03.12	Bayer: EYLEA in Australien zur Behandlung der feuchten altersbedingten Makula-Degeneration zugelassen (Aktiencheck)
20.02.12	Bayer: Ergebnisse von Phase-III-Studie mit VEGF Trap-Eye bei Zentralvenenverschluss der Netzhaut positiv (Aktiencheck)
28.11.11	UPDATE: Bayer will Augenmittel auch in China vermarkten (Dow Jones)
28.11.11	Bayer führt Phase III-Studie für VEGF Trap-Eye in China durch (Dow Jones)
04.08.09	Regeneron Reports Second Quarter 2009 Financial and Operating Results (Businesswire)
30.04.09	Regeneron Reports First Quarter 2009 Financial and Operating Results (Businesswire)
31.07.08	Regeneron Reports Second Quarter 2008 Financial and Operating Results (Businesswire)
27.02.08	FDA Approves Regeneron's ARCALYST(TM) (rilonacept) for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) (Businesswire)
03.08.07	Regeneron and Bayer HealthCare Initiate Phase 3 Global Development Program For VEGF Trap-Eye In Wet Age-Related Macular Degeneration (AMD) (Businesswire)
01.08.07	Regeneron Reports Second Quarter Financial and Operating Results (Businesswire)
03.05.05	Clinical and Pre-Clinical Studies of the VEGF Trap Show Potential for (Businesswire)
28.03.05	Regeneron Announces Presentation at the Lehman Brothers Eighth Annual (Businesswire)
22.02.05	Regeneron Reports Fourth Quarter and Full Year 2004 Financial and Oper (Businesswire)
10.01.05	Sanofi-aventis Reaffirms Commitment to Alliance with Regeneron Pharmac (Businesswire)
07.01.05	Regeneron Announces Presentation at the 23rd Annual JPMorgan Healthcar (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

19.11.24		Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen
31.10.24		NASDAQ-Handel NASDAQ 100 schlussendlich in Rot
31.10.24		NASDAQ Composite-Handel aktuell: NASDAQ Composite am Donnerstagnachmittag in der Verlustzone
31.10.24		NASDAQ 100-Handel aktuell: Das macht der NASDAQ 100 aktuell
31.10.24		Zurückhaltung in New York: So performt der NASDAQ 100 aktuell
31.10.24		Angespannte Stimmung in New York: NASDAQ Composite liegt mittags im Minus
31.10.24		Zurückhaltung in New York: NASDAQ 100 zum Handelsstart im Minus
31.10.24		Donnerstagshandel in New York: NASDAQ Composite verliert zum Handelsstart

19.11.24

Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen

31.10.24

NASDAQ-Handel NASDAQ 100 schlussendlich in Rot

31.10.24

NASDAQ Composite-Handel aktuell: NASDAQ Composite am Donnerstagnachmittag in der Verlustzone

31.10.24

NASDAQ 100-Handel aktuell: Das macht der NASDAQ 100 aktuell

31.10.24

Zurückhaltung in New York: So performt der NASDAQ 100 aktuell

31.10.24

Angespannte Stimmung in New York: NASDAQ Composite liegt mittags im Minus